Federal Report Exposes the Financial Interests Behind Procedures on Minors
A new federal report is raising troubling questions about the financial interests surrounding gender-related drugs and procedures for children.
On August 13, the Department of Health and Human Services released a report alleging that hospitals and healthcare providers submitted tens of millions of dollars in insurance claims for puberty blockers and related treatments involving minors. According to HHS, some claims were filed using codes for unspecified endocrine disorders or precocious puberty rather than gender dysphoria.
The details involve medical billing, but the larger issue is much more important.
Hospitals, clinics, pharmaceutical companies, and medical providers can receive significant revenue from placing children on a treatment path involving repeated appointments, prescription drugs, monitoring, and potentially irreversible procedures. When an institution benefits financially from providing a treatment, families have every right to question whether that financial interest is influencing how the treatment is promoted.
Children Should Never Become a Revenue Stream
Children experiencing distress deserve compassion, patience, and careful support. They should not be treated as potential customers for a continuing series of medical interventions.
Once a child enters this system, the treatment may extend across years. Each appointment, prescription, consultation, and procedure can generate additional revenue for the institutions involved.
That financial structure creates a serious conflict of interest. The same organizations recommending these interventions may also benefit financially when families agree to them.
Parents Deserve Advice They Can Trust
Parents facing difficult decisions should be able to trust that medical recommendations are based entirely on the long-term welfare of their child.
Financial incentives can undermine that trust.
Families may not be told how much an institution stands to earn, how long treatment could continue, or how medical organizations benefit when more children are placed on these pathways.
A child’s vulnerability should never become another institution’s business opportunity.
Missouri Can Remove the Financial Incentive
Amendment 3 would prohibit puberty blockers, cross-sex hormones, and gender-transition procedures for minors in Missouri while preserving the freedom of consenting adults to make their own decisions.
By prohibiting these interventions for children, Missouri would do more than establish an age boundary. It would prevent hospitals and providers from building a profitable market around vulnerable minors.
Medical institutions could no longer lawfully provide the prohibited procedures to children and then collect revenue from the treatments that follow.
The individual billing allegations in the HHS report still deserve a full and fair investigation. But Missouri does not have to wait for a final legal finding to recognize the larger danger created when medical institutions are allowed to profit from experimental and potentially life-altering interventions involving children.
Protect Children Before More Harm Is Done
The federal report offers another warning about what can happen when ideology, institutional influence, and financial incentives converge.
Children deserve time to grow and mature without being drawn into a medical system that can profit from their distress. Parents deserve guidance free from conflicting financial interests. Missouri has an opportunity to act before more children are placed at risk.
Her Health Her Future supports policies that protect children, strengthen parental rights, and remove the financial incentive to prescribe or promote these interventions to minors.
Pass Amendment 3. End the financial incentive. Protect Missouri’s children.
Official HHS report: https://www.hhs.gov/press-room/hhs-report-insurance-coding-sex-rejecting-procedures-minors.html
